Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immix Biopharma, Inc. - Common Stock (NQ:IMMX)

1.640 +0.070 (+4.46%)
Streaming Delayed Price Updated: 3:15 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 16,597
Open 1.600
Bid (Size) 1.570 (5)
Ask (Size) 1.790 (1)
Prev. Close 1.570
Today's Range 1.600 - 1.689
52wk Range 1.260 - 2.710
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T
From Immix Biopharma, Inc.
Via GlobeNewswire

Performance

YTD
-25.5%
-25.5%
1 Month
-15.9%
-15.9%
3 Month
-19.6%
-19.6%
6 Month
-4.7%
-4.7%
1 Year
-25.8%
-25.8%

More News

Read More
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
From Immix Biopharma, Inc.
Via GlobeNewswire
IMMX Stock Earnings: Immix Biopharma Beats EPS for Q2 2024
Via InvestorPlace
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
From Immix Biopharma, Inc.
Via GlobeNewswire
IMMX Stock Earnings: Immix Biopharma Beats EPS for Q1 2024
Via InvestorPlace
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma on Track to Dose NXC-201 Patients in United States
From Immix Biopharma, Inc.
Via GlobeNewswire
IMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023
Via InvestorPlace
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
From Immix Biopharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Immix Biopharma Inc. (NASDAQ: IMMX) Closes on $15M Public Offering
Via Investor Brand Network
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Announces Proposed Public Offering of Common Stock
From Immix Biopharma, Inc.
Via GlobeNewswire
Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga

Frequently Asked Questions

Is Immix Biopharma, Inc. - Common Stock publicly traded?
Yes, Immix Biopharma, Inc. - Common Stock is publicly traded.
What exchange does Immix Biopharma, Inc. - Common Stock trade on?
Immix Biopharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Immix Biopharma, Inc. - Common Stock?
The ticker symbol for Immix Biopharma, Inc. - Common Stock is IMMX on the Nasdaq Stock Market
What is the current price of Immix Biopharma, Inc. - Common Stock?
The current price of Immix Biopharma, Inc. - Common Stock is 1.640
When was Immix Biopharma, Inc. - Common Stock last traded?
The last trade of Immix Biopharma, Inc. - Common Stock was at 04/17/25 03:15 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.